- Home
- RIGL vs PRTC Comparison
RIGL vs PRTC Comparison
Compare RIGL & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- PRTC
- Stock Information
- Founded
- RIGL 1996
- PRTC 2015
- Country
- RIGL United States
- PRTC United States
- Employees
- RIGL N/A
- PRTC N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- PRTC Health Care
- Exchange
- RIGL Nasdaq
- PRTC Nasdaq
- Market Cap
- RIGL 486.4M
- PRTC 431.0M
- IPO Year
- RIGL 2000
- PRTC N/A
- Fundamental
- Price
- RIGL $20.99
- PRTC $19.16
- Analyst Decision
- RIGL Buy
- PRTC Buy
- Analyst Count
- RIGL 5
- PRTC 1
- Target Price
- RIGL $34.80
- PRTC $45.00
- AVG Volume (30 Days)
- RIGL 216.6K
- PRTC 3.3K
- Earning Date
- RIGL 03-04-2025
- PRTC 08-28-2024
- Dividend Yield
- RIGL N/A
- PRTC N/A
- EPS Growth
- RIGL N/A
- PRTC N/A
- EPS
- RIGL 0.22
- PRTC N/A
- Revenue
- RIGL $157,374,000.00
- PRTC $468,000.00
- Revenue This Year
- RIGL $51.34
- PRTC N/A
- Revenue Next Year
- RIGL $15.75
- PRTC $160.00
- P/E Ratio
- RIGL $94.25
- PRTC N/A
- Revenue Growth
- RIGL 21.65
- PRTC N/A
- 52 Week Low
- RIGL $7.48
- PRTC $17.00
- 52 Week High
- RIGL $29.82
- PRTC $34.00
- Technical
- Relative Strength Index (RSI)
- RIGL 55.77
- PRTC 52.70
- Support Level
- RIGL $20.98
- PRTC $18.80
- Resistance Level
- RIGL $23.01
- PRTC $19.53
- Average True Range (ATR)
- RIGL 1.40
- PRTC 0.33
- MACD
- RIGL 0.31
- PRTC 0.28
- Stochastic Oscillator
- RIGL 70.13
- PRTC 85.38
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About PRTC PureTech Health plc
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.